AU1763201A - Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery - Google Patents

Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery

Info

Publication number
AU1763201A
AU1763201A AU17632/01A AU1763201A AU1763201A AU 1763201 A AU1763201 A AU 1763201A AU 17632/01 A AU17632/01 A AU 17632/01A AU 1763201 A AU1763201 A AU 1763201A AU 1763201 A AU1763201 A AU 1763201A
Authority
AU
Australia
Prior art keywords
diseases
modulation
target
treatment
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17632/01A
Inventor
Christen M. Anderson
David K. Becker
William Clevenger
Kathryn A. Grako
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Migenix Corp
Original Assignee
Mitokor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokor Inc filed Critical Mitokor Inc
Publication of AU1763201A publication Critical patent/AU1763201A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
AU17632/01A 1999-11-10 2000-11-13 Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery Abandoned AU1763201A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16453399P 1999-11-10 1999-11-10
US60164533 1999-11-10
PCT/US2000/031119 WO2001035096A2 (en) 1999-11-10 2000-11-13 Diseases associated with altered mitochondrial function

Publications (1)

Publication Number Publication Date
AU1763201A true AU1763201A (en) 2001-06-06

Family

ID=22594937

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17632/01A Abandoned AU1763201A (en) 1999-11-10 2000-11-13 Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery

Country Status (2)

Country Link
AU (1) AU1763201A (en)
WO (1) WO2001035096A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118873B2 (en) 2000-12-12 2006-10-10 The University Of Connecticut Polynucleotides encoding cellular transporters and methods of use thereof
JP4105626B2 (en) * 2001-05-29 2008-06-25 ザ ユニバーシティ オブ ブリティッシュ コロンビア Pharmacological application of mitochondrial DNA assay
AU2002311013A1 (en) * 2001-06-08 2002-12-23 Novo Nordisk A/S Dna encoding a mutant peroxisome proliferator-activated receptor gamma coactivator-1 (pgc-1), detection methods and test kits therefor
EP1264841A1 (en) * 2001-06-08 2002-12-11 Novo Nordisk A/S DNA encoding a mutant peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1), detection methods and test kits therefor
EP1412374B1 (en) * 2001-07-05 2010-09-08 Dana-Farber Cancer Institute, Inc. Novel pgc-1 isoforms and uses therefor
WO2004000313A2 (en) * 2002-06-24 2003-12-31 Exonhit Therapeutics Sa Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds
WO2005003766A2 (en) * 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Methods of regulating metabolism and mitochondrial function
KR101838305B1 (en) * 2009-12-29 2018-03-13 큐알엔에이, 인크. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
US20120329761A1 (en) * 2010-03-10 2012-12-27 University Health Network Use of tigecycline for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031396A1 (en) * 1997-01-15 1998-07-23 Duke University Respiration uncoupling protein
CA2290944C (en) * 1997-05-30 2012-03-06 Bruce M. Spiegelman Pgc-1, a novel brown fat ppar.gamma. coactivator
SE9702457D0 (en) * 1997-06-26 1997-06-26 Pharmacia & Upjohn Ab screening
FR2767058B1 (en) * 1997-08-05 2000-05-05 Centre Nat Rech Scient USE OF A RETINOID-LIKE COMPOUND, IN PARTICULAR RETINOIC ACID FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF OBESITY.

Also Published As

Publication number Publication date
WO2001035096A3 (en) 2001-11-29
WO2001035096A2 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
AU2180400A (en) A pharmaceutical combination for the treatment of depression
AU7735200A (en) Treatment of tissue by application of energy and drugs
AU3076700A (en) 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU2039800A (en) 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins
AU3009801A (en) Combinations of medicaments for treating viral diseases
AU2002252227A1 (en) Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
AU2508597A (en) Drug for the treatment of tumours
AU9551298A (en) Use of coumarin derivatives for the treatment of digestive tract disorders
NO20003229D0 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for the treatment of proliferative diseases
AU6858996A (en) Pharmaceutical compositions for the treatment of infectious diseases
AU7731700A (en) Low dose ifn-gamma for treatment of disease
AU1763201A (en) Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
AU3366899A (en) Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
AU2001258395A1 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
AU5820900A (en) Capsule for the controlled release of active substances
AU3896900A (en) Treatment of pain
AU1955201A (en) Insecticide targets and methods of use
AU2432001A (en) Treatment of mental conditions including depression
AU3760900A (en) Treatment of menstrual function
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
AU4145999A (en) Topical drug for the treatment of viral infections
AU2001262741A1 (en) Medicines for the prevention and treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase